Background: The 2022–23 US influenza season peaked early in fall 2022.Methods: Late‐season influenza vaccine effectiveness (VE) against outpatient, laboratory‐confirmed influenza was calculated among participants of the US Influenza VE Network using a test‐negative design.Results: Of 2561 participants enrolled from December 12, 2022 to April 30, 2023, 91 laboratory‐confirmed influenza cases primarily had A(H1N1)pdm09 (6B.1A.5a.2a.1) or A(H3N2) (3C.2a1b.2a.2b). Overall, VE was 30% (95% confidence interval −9%, 54%); low late‐season activity precluded estimation for most subgroups.Conclusions: 2022–23 late‐season outpatient influenza VE was not statistically significant. Genomic characterization may improve the identification of influenza viruses that circulate postinfluenza peak.
As surges in the COVID‐19 pandemic have continued worldwide, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has mutated, spawning several new variants, and impacting, to various degrees, transmission, disease severity, diagnostics, therapeutics, and natural and vaccine‐induced immunity. Baylor Scott & White Health has implemented, along with laboratory diagnosis, SARS‐CoV‐2 sequencing to identify variants in its geographical service area. We analyzed virus sequencing results of specimens collected across Central Texas and found dramatic changes in variant distribution in the first half of 2021. The alpha variant (B 1.1.7) became predominant at week 13 and continued dominance until week 25. A growth rate of 1.20 (R2 = 0.92) for the first 15 weeks was noted and this growth gradually declined to −0.55 (R2 = 0.99) for the final 13 weeks. Currently, B.1.1.7 is being displaced with B.1.617.2 at a 0.58 growth rate (R2 = 0.97). We also investigated vaccine breakthrough cases (VBCs) within our healthcare system and present clinical data on 28 symptomatic patients.
Introduction: Rapid diagnosis and isolation are key to containing the rapid spread of a pandemic agent like SARS-CoV-2, which has spread globally since its initial outbreak in Wuhan province in China. SARS-CoV-2 is novel to most parts of the world including USA and the effect on normally prevalent viruses is just becoming apparent. We present our initial data on the prevalence of respiratory viruses in the month of March, 2020. Methods: This is a retrospective cohort study post launching of SARS-CoV-2 testing at BSWH, Temple TX. Testing for SARS-CoV-2 was performed by real-time RT-PCR assay and results were shared with State public health officials for immediate interventions. Results: More than 3500 tests were performed during the first two weeks of testing for SARS-CoV-2 and identified 168 (4.7%) positive patients. Sixty-two (3.2%) of the 1,912 ambulatory patients and 106 (6.3%) of the 1,659 ED/inpatients were tested positive. Higher rate of infection (6.9%) were noted in the patients belonging to age group 25-34 years and least number of positive cases were noted in <25 years old (2%) group. The TX State county specific patient demographic information was shared with respective public health departments for epidemiological interventions. Incidentally, this study showed that there was a sudden decrease in the occurrence of other infections due to seasonal viruses, perhaps due to increased epidemiological awareness, about SARS-CoV-2, among general public. Authors would also like to share a small study on SARS-CoV-2 serological assay for the detection of IgG antibodies. Conclusions: This study was intended to provide an initial experience of dealing with a pandemic and the role of laboratories in crisis management. Epidemiological interventions depend on timely availability of accurate diagnostic tests and throughput capacity of such systems during large outbreaks like SARS-CoV-2.
Acinetobacter baumannii most often causes pneumonia in critically ill patients. However, A. baumannii is also an important cause of a broader range of infections, including skin/wound and urinary tract infections. This study aims to evaluate the in vitro activity of sulbactam-durlobactam and comparator antibiotics, including meropenem and cefiderocol against A. baumannii-calcoaceticus complex isolates from non-respiratory and non-bloodstream sources. Samples included 285 A. baumannii-calcoaceticus complex isolates enriched for carbapenem resistance collected across 17 states in the United States (January 2023–May 2025). Antimicrobial susceptibility tests were conducted by manual broth microdilution and interpreted according to Clinical and Laboratory Standards Institute (CLSI) and Food and Drug Administration (FDA) (cefiderocol) standards. A. baumannii complex isolates were primarily cultured from skin/wound (58.6%), urinary tract (31.6%), and other sources (9.8%), including cerebrospinal and peritoneal fluid. Carbapenem resistance was observed in approximately 70% of isolates and more common among skin/wound cultures. Sulbactam-durlobactam was observed to be highly active (96.9% susceptible [S]; MIC 90 4 mg/L) and demonstrated greater activity than sulbactam (37.9% S; MIC 90 32 mg/L). Sulbactam-durlobactam also displayed high susceptibility rates across isolate sources, ranging from 96.4 (skin/wound) to 97.8% (urine). Cefiderocol demonstrated similar in vitro activity across culture sources and patient location, inhibiting >90 and >80% of isolates at CLSI and FDA susceptible breakpoints, respectively. Minocycline susceptibility was 69.1%, while tigecycline and eravacycline MICs 50/90 were 1/4 and 0.5/1 mg/L, respectively. The observed data are consistent with results from surveillance studies among respiratory and bloodstream isolates and show that sulbactam-durlobactam demonstrates potent in vitro activity against clinical A. baumannii complex isolates from a variety of culture sources. IMPORTANCE: Acinetobacter baumannii is a difficult-to-treat pathogen that often affects hospitalized patients and is known for a high level of multi-drug resistance. While commonly associated with pneumonia, it also causes infections in wounds, the urinary tract, and other parts of the body. This study shows that sulbactam-durlobactam is highly effective against A. baumannii from various infection sites. The results are important because they can inform clinicians on the susceptibility profiles of A. baumannii from a variety of infection sources, not just lung and bloodstream. As new antibiotics come onto the market, it is important to continuously assess resistance patterns to inform patient and system-wide health decisions.